NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor

Tomoko Niwa¹, Tetsuo Asaki¹ and Shinya Kimura²

¹Discovery Research Laboratories, Nippon Shinyaku Co., Ltd. 14, Nishinosho-Monguchi-Cho, Kisshoin, Minami-ku, Kyoto 601-8550, Japan. ²Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyoku, Kyoto 600-8507, Japan.

Abstract: Protein kinases catalyze the transfer of the γ-phosphoryl group of adenosine triphosphate (ATP) to the hydroxyl groups of protein side chains, and they play critical roles in regulating cellular signal transduction and other biochemical processes. They are attractive targets for today’s drug discovery and development, and many pharmaceutical companies are intensively developing various kinds of protein kinase inhibitors. A good example is the recent success with the Bcr-Abl tyrosine kinase inhibitor imatinib mesylate (Gleevec™) in the treatment of chronic myeloid leukemia. Though imatinib has dramatically improved the treatment of Bcr-Abl-positive chronic myeloid leukemia, resistance is often found in patients with advanced-stage disease. Several mechanisms have been proposed to explain this resistance, including point mutations within the Abl kinase domain, amplification of the bcr-abl gene, overexpression of the corresponding mRNA, increased drug efflux mediated by P-glycoprotein, and activation of the Src-family kinase (SFK) Lyn. We set out to develop a novel drug whose affinity for Abl is higher than that of imatinib and whose specificity in inhibiting Lyn is higher than that of SFK/Abl inhibitors such as dasatinib (Sprycel™) or bosutinib (SKI-606). Our work has led to the development of NS-187 (INNO-406), a novel Abl/Lyn dual tyrosine kinase inhibitor with clinical prospects. To provide an overview of how a selective kinase inhibitor has been developed, this review presents chemical-modification studies carried out with the guidance of molecular modeling, the structural basis for the high potency and selectivity of NS-187 based on the X-ray structure of the NS-187/Abl complex, and the biological profiling of NS-187, including site-directed mutagenesis experiments.

Keywords: NS-187, INNO-406, imatinib, chronic myeloid leukemia, Bcr-Abl, Lyn

Introduction

Protein kinases play critical roles in regulating cellular signal transduction and other biochemical processes by catalyzing the transfer of the γ-phosphoryl group of adenosine triphosphate (ATP) to the hydroxyl groups of protein side chains. They are therefore attractive targets for today’s drug discovery and development, and many pharmaceutical companies are intensively developing kinase inhibitors that may have therapeutic value (Cohen, 2002). A good example is imatinib mesylate (Gleevec™), a specific inhibitor of breakpoint cluster region—Abelson tyrosine kinase (Bcr-Abl TK) (Buchdunger et al. 1996). Imatinib (Fig. 1) is efficacious in the treatment of Philadelphia-chromosome—positive (Ph⁺) leukemias such as chronic myeloid leukemia and Ph⁺ acute lymphoblastic leukemia (Goldman et al. 2003; Kimura et al. 2006). Philadelphia chromosome is a specific chromosomal abnormality resulting from a reciprocal translocation between chromosomes 9 and 22. This translocation fuses the c-abl proto-oncogene to bcr, leading to the production of a Bcr-Abl fusion protein that constitutively activates multiple signaling pathways. Because most patients with chronic myeloid leukemia have this abnormality, Bcr-Abl tyrosine kinase is a promising target for treating Ph⁺ leukemias (Sawyers, 1999).

Within a few years of its introduction to the clinic, imatinib had dramatically altered the first-line therapy for chronic myeloid leukemia, because most patients newly diagnosed with this disease in the chronic phase achieve durable responses when treated with imatinib (O’Brien et al. 2003). However, a small percentage of these patients, as well as most patients with advanced-phase chronic myeloid leukemia and Ph⁺ acute lymphoblastic leukemia, relapse on imatinib therapy (Druker et al. 2002; Ottmann et al. 2002). Several mechanisms have been proposed to explain the cases of refractory disease and relapse, including point mutations within the Abl kinase domain, amplification of the bcr-abl gene, overexpression of the corresponding mRNA (Gorre et al. 2001; Hofmann et al. 2002; Nardi et al. 2004;
Deininger et al. (2005), increased drug efflux from the target cells mediated by P-glycoprotein (P-gp) (Hegedus et al. 2002), and activation of Lyn, a Src-family protein kinase (SFK) (Donato et al. 2003; Dai et al. 2004; Ptasznik et al. 2004).

To overcome imatinib resistance, higher doses of imatinib and combination therapy with other agents have been used, with some efficacy. However, these strategies are limited in their application and effectiveness, especially for patients with mutations in the Abl kinase domain (Cortes et al. 2003; Kantarjian et al. 2004; O’Brien et al. 2003b). Therefore it is necessary to develop more-effective Abl TK inhibitors. Several SFK inhibitors from various chemical classes, including PD166326 (Wisniewski et al. 2002), SKI-606 (Golas et al. 2003), AP23464 (O’Hare et al. 2004), and dasatinib (Sprycel™, formerly BMS-354825) (Shah et al. 2004) have been reported to be 100–300 times more effective than imatinib in blocking Bcr-Abl TK autophosphorylation, and this inhibition of autophosphorylation extends to point mutants of Bcr-Abl. However, while imatinib binds only to the inactive form of Bcr-Abl, these SFK/Abl inhibitors bind also to the active form, which shares considerable conformational similarity with the active forms of diverse kinases, including the SFKs (Nagar et al. 2003). This characteristic of SFK/Abl inhibitors has some advantage with respect to Lyn kinase, because overexpression of Lyn may be associated with imatinib resistance (Donato et al. 2003; Dai et al. 2004; Ptasznik et al. 2004). However, the effects of lower specificity against SFKs are not yet fully understood, because these kinases play many important roles in vivo (Cary et al. 2002; Davis et al. 2003; Tanaka et al. 1996; Touyz et al. 2001). In addition to these SFK/Abl inhibitors, nilotinib (Tasigna™; formerly AMN107) has been developed as a novel Abl TK inhibitor. The in vitro inhibitory effect of nilotinib is 10–30 times greater than that of imatinib, but it is weaker than that of SFK/Abl inhibitors (Weisberg et al. 2005). Therefore, we set out to develop a drug whose affinity for Abl is higher than that of imatinib and whose specificity in inhibiting Lyn at clinically relevant concentrations without affecting the phosphorylation of other SFKs is greater than that of other SFK/Abl inhibitors.

**Structural Analysis of Kinases**

Protein kinases are attractive targets for drug discovery programs in many disease areas, and most kinase inhibitors under development act by directly competing with ATP at the ATP-binding site of kinases. However, there are more than 500 protein kinases (Manning et al. 2002), and the ATP-binding site is highly conserved among them. Selectivity is therefore an essential requirement for clinically
effective drugs targeted against protein kinases, and it is crucial to understand the structural characteristics of the ATP-binding site. Because kinase inhibitors on the market and currently under development often lack a portion to interact with the phosphate-binding region of the ATP-binding site, the term “ligand-binding site” will be used hereinafter instead of the term “ATP-binding site”.

X-ray crystallography is a promising method for understanding the structural and physicochemical characteristics of the ligand-binding sites of protein kinases, and we have closely examined the X-ray structure of the imatinib/Abl complex. We first explored the ligand-binding site by using the 3D atomic coordinates of Abl kinase (Nagar et al. 2002), and then we calculated the surface properties of the binding site with a molecular modeling suite of MOE (Chemical Computing Group, Inc.). In Figure 2, the spheres indicate the predicted locations of an inhibitor’s atoms, and imatinib is shown for reference. The spheres are classified as either hydrophilic (red) or hydrophobic (white) depending on whether or not they are in good hydrogen-bonding locations. Green, blue, and red express the hydrophobic, hydrophilic, and exposed nature of the surface, respectively. A large part of the surface is shown in green, indicating the hydrophobic nature of the ligand-binding site of Abl.

The five rings in imatinib were labeled A through E as shown in Figure 1, and the region of the binding site around the A and B rings is shown in Figure 2A. The positions and properties of the spheres in this region correspond well to those of the A and B rings of imatinib, and there is limited space for chemical modification. There is also limited space around the C ring. In contrast, much space is available around the D ring, suggesting the feasibility of an intensive program of chemical modification of this part of the molecule (Fig. 2B). The surface color of the part of the binding site adjacent to the terminal E ring of imatinib is blue, indicating that hydrogen-bonding interactions are probably important for the binding of the E ring (Fig. 2C).

Though X-ray crystallography is very helpful for understanding the structural and physicochemical characteristics of ligand-binding sites, a sufficient number of X-ray crystallographic structures for exhaustive comparison of the binding sites of various kinases is not yet available. The only data generally available for any kinase is the amino acid sequence, and, accordingly, sequence similarity is widely used for classifying proteins and predicting biological activities (Hank et al. 1988; Hank et al. 1991). However, it is difficult to elucidate the structural characteristics of a ligand-binding site from the amino acid sequence alone.

We have developed a procedure to overcome this difficulty by using physicochemical descriptors of amino acids in conjunction with neural network modeling (Niwa, 2006). The physicochemical properties of amino acids were expressed by hydrophobic, steric and structural descriptors. Kinases are classified into four major groups based on sequence similarity, AGC (PKA, PKG, and PKC families), CaMK (calcium/calmodulin-dependent protein kinases), CMGC (CDK, MAPK, GSK3, and CLK families), and TK (Hank et al. 1988). Abl kinase belongs to the TK group, so we aimed to elucidate which amino acids and which properties characterize the ligand-binding sites of TK, and to visualize the results by molecular graphics. TK ligand-binding sites are characterized by the branched nature of the side chains of the amino acids at positions 313 and 315. The methyl group of the C ring of imatinib and similar tyrosine kinase inhibitors, known as the “flag methyl”, makes a large contribution to both their inhibitory activity and their selectivity (Zimmermann et al. 1997). The C ring and the flag methyl are located close to the amino acids at positions 313 and 315. Another characteristic feature of the TK ligand-binding site is the short side chain of the amino acid at position 322, which forms a hydrogen bond with Tyr253 and helps to stabilize the inactive conformation of Bcr-Abl kinase. Based on the above results, we developed guidelines for the chemical modification of Abl kinase ligands (Fig. 3). Though they are rather rough guidelines, they have helped us to understand the structural characteristics of the binding site of Abl kinase. In addition, they helped us to decide at the beginning of the project which kinds of chemical modifications were likely to be useful.

Chemical Modification
To guide our chemical-modification studies, we used the reported X-ray structure of the imatinib/Abl complex (Nagar et al. 2002). When we closely examined the structure, we found a hydrophobic pocket formed by amino acids Ile293, Leu298, Leu354 and Val379 around the phenyl (D) ring of imatinib. To improve the antiproliferative activity of imatinib against Bcr-Abl-positive (Bcr-Abl+) leuke-
mia cell lines, we focused on this hydrophobic pocket
and introduced various hydrophobic substituents on
the phenyl (D) ring (Asaki et al. 2006). We found that
3-halogenated and 3-trifluoromethylated derivatives
have significantly increased inhibitory activity com-
pared to unsubstituted imatinib (Table 1).

To compensate for the increase in hydrophobicity
caused by the introduction of the hydrophobic tri-
fluoromethyl group in 5e, the distal pyridine (A) ring
was selected for further modification. In the crystal
structure of the imatinib/Abl complex, Tyr253 is
located very close to the A ring, and their interaction
helps to stabilize the inactive form of the kinase.
Therefore, a structural modification that increases
the bulk in this region would be expected to be unfa-
vorable. The pyridine ring was therefore replaced by
the more hydrophilic pyrimidine ring. Pyrimidine
derivative 9a displayed activity (IC$_{50}$ = 4 nM) similar
to the original pyridine derivative 5e, showing that
pyrimidinyl substitution is compatible with the reten-
tion of inhibitory activity.

The crystal structure of the complex reveals
that the piperazine moiety (E) of imatinib interacts
with the carbonyl oxygen atoms of Ile360 and
His361 through hydrogen bonding. Taking
account of this important interaction, we replaced
the piperazine moiety in 9a with other cyclic
amines. The optically pure 3-(dimethylamino)
pyrrolidine derivatives 9b and 9c, the 3-(dimeth-
ylaminomethyl)pyrrolidine derivatives 9d and 9e,
and the 3-(dimethylamino)azetidine derivative
9f, all of whose E-ring systems had the potential
to function as piperazine isosteres, were synthe-
sized (Fig. 4). The pyrrolidine derivative 9c

![Figure 2. Structural properties of Abl kinase ligand-binding sites. Spheres indicate the probable locations of ligand atoms, and are classified as either hydrophilic (red) or hydrophobic (white) depending on whether or not they are in good hydrogen-bonding locations. The surface colors green, blue, and red represent the hydrophobic, hydrophilic, and exposed nature of the surface, respectively.](image)

Figure 2.

![Figure 3. Guidelines for chemical modification.](image)

Figure 3.
exhibited excellent potency (IC$_{50}$ = 4 nM), comparable to 9a. Compound 9b, the enantiomer of 9c, and other pyridine derivatives (9d and 9e) had lower, though still excellent, antiproliferative activity (IC$_{50}$ = 11, 11 and 9 nM, respectively). Azetidine 9f had lower potency still (IC$_{50}$ = 17 nM). These results reveal that the antiproliferative activity is somewhat affected by the position of the terminal dimethylamino function. In other words, the differences in activity among these compounds may be attributed to subtle differences in the distance between the dimethylamino function and the carbonyl oxygen atoms of Ile360 and His361.

At the beginning of our project, the involvement of Lyn kinase in imatinib resistance was unknown. In 2003, Donato et al. reported the association of the overexpression of Lyn kinase with imatinib resistance (Donato et al. 2003; Dai et al. 2004; Ptasznik et al. 2004). Thereafter, we tried to develop Abl/Lyn dual inhibitors, and found that NS-187 (9b; INNO-406) and its derivatives also inhibit Lyn kinase. To investigate why this series of compounds act as dual Bcr-Abl/Lyn kinase inhibitors, we determined their inhibitory activities against Abl and Lyn kinases and studied their structure-activity relationships (Horio et al. 2007). All compounds tested show more-potent inhibitory activity against Abl and Lyn than does imatinib (Table 1), and the inhibitory activities of 3-substituted benzamides against Abl and Lyn are highly correlated (r = 0.982 when the activity is expressed as pIC$_{50}$).

Judging from its overall characteristics, including its pharmacokinetics and toxicity as determined in animal studies, we selected 9b (NS-187) as a candidate for clinical development (Kimura et al. 2005; Asaki et al. 2006). NS-187 is

### Table 1. Inhibitory and antiproliferative activity of 3-substituted benzamide derivatives.

| Compound | X  | R$^1$ | R$^2$ | IC$_{50}$ (nM) |
|----------|----|-------|-------|---------------|
|          |    |       |       | K562 cells (Bcr-Abl)$^a$ | U937 cells$^a$ | Abl$^b$ | Lyn$^b$ |
| imatinib | CH | H     | MeN   | 182           | 14,000       | 220    | 470    |
| 5a       | CH | F     | MeN   | 63           | 8,000        | 35     | 120    |
| 5b       | CH | Cl    | MeN   | 10           | 9,000        | N.D.   | N.D.   |
| 5c       | CH | Br    | MeN   | 7            | 5,000        | 3.1    | 12     |
| 5d       | CH | I     | MeN   | 10           | 6,000        | N.D.   | N.D.   |
| 5e       | CH | CF$_3$| MeN   | 5            | 4,000        | 4.8    | 5.1    |
| 9a (NS-187) | N | CF$_3$| MeN   | 4            | 5,000        | 8.5    | 8.8    |
| 9b        | N  | CF$_3$| MeN   | 11           | 10,000       | 11     | 26     |
| 9c$^d$   | N  | CF$_3$| MeN   | 4            | 9,000        | 3.4    | 12     |
| 9d$^d$   | N  | CF$_3$| MeN   | 11           | 20,000       | N.D.   | N.D.   |
| 9e$^d$   | N  | CF$_3$| MeN   | 9            | >100,000     | 7.6    | 32     |
| 9f$^d$   | N  | CF$_3$| MeN   | 17           | >100,000     | 29     | 140    |

$^a$IC$_{50}$ represents the concentration of compound which inhibits cell proliferation by 50%.

$^b$IC$_{50}$ represents the concentration of compound which inhibits the kinase activity by 50%.

$^c$ND, not determined. $^d$The biological activity of the monohydrochloride salts was evaluated.

Adapted from Asaki et al. 2006 and Horio et al. 2006.
now under investigation in a Phase I clinical trial with Ph+ leukemia.

**Structural Analysis of NS-187**

**X-ray structure of NS-187 bound to human Abl**

We recently determined the X-ray structure of NS-187 bound to human Abl (Niwa et al. 2007) shown in Figure 5B (Abl, blue; NS-187, yellow). For comparison, the X-ray structure of imatinib bound to Abl (Abl, cyan; imatinib, white) is shown in Figure 5A. Only the amino acids within 4 Å of NS-187 or imatinib are depicted for clarity. The two X-ray structures resemble each other very closely, with only slight differences in the positions of the ligands and the side chains and backbones of the kinases. Therefore it is clear that NS-187 and imatinib interact with Abl in very similar ways. This finding validates our use of the X-ray structure of the imatinib/Abl complex to guide our chemical-modification studies.

We checked whether our strategy for chemical modification was appropriate by analyzing the X-ray structure of the NS-187/Abl complex (Fig. 5C). The trifluoromethyl (CF$_3$) group is well placed to interact with the hydrophobic pocket formed by Ile293, Leu298, Leu354, and Val379, shown in magenta. Tyr253 is located close to the pyrimidine (A) ring, so that our use of a pyrimidine instead of a pyridine ring does not appear to alter the important role of Tyr253 in stabilizing the inactive form of the kinase. Hydrogen-bonding interactions are shown as broken white lines in Figure 5C, and it can be seen that the nitrogen atom of the dimethylamino group is well placed to interact with the carbonyl oxygen atoms of Ile360 and His361 through hydrogen bonding. Our strategy for chemical modification was thus validated.

**Effects of the CF$_3$ group of NS-187**

The 3-substituents (R$_1$) on the D ring greatly enhance the inhibitory activity against both Abl and Lyn kinases (Table 1). To elucidate this effect, we quantitatively analyzed the effect of the 3-substituent
NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor

Analytical Chemistry Insights 2007:2

on the inhibitory activity of the compounds against Abl and Lyn kinases by using various physicochemical parameters of the 3-substituents. We found that the inhibitory activity is highly correlated with the hydrophobic substituent parameter $\pi$ (correlation coefficient $r = 0.958$ for Abl and $r = 0.977$ for Lyn) (Horio et al. 2007). This means that the inhibitory effect increases with the hydrophobicity of the 3-substituent.

To understand this effect more clearly, we examined the molecular surfaces of Abl and Lyn kinases near the 3-substituent (Fig. 5D–F). It is apparent that there remains room to accommodate chemical modification of the D ring in the hydrophobic pocket formed by the amino acids Ile293, Leu298, Leu354 and Val379, shown in magenta in the X-ray structure of the imatinib/Abl complex (Fig. 5D). However, in the X-ray structure of the NS-187/Abl complex, the CF$_3$ group occupies this hydrophobic pocket well (Fig. 5E). The modeled structure of the NS-187/Lyn complex, which is based on the X-ray structure of the NS-187/Abl complex, is depicted in Figure 5F. Close to the 3-substituent there are four hydrophobic amino acids, Leu293, Leu298, Ile354 and Ile379, shown in magenta (Horio et al. 2007). Although the identities of three of the four amino acids differ between Abl and Lyn, they are all hydrophobic amino acids. Therefore it is likely that the enhanced inhibitory activity of the modified compounds against both Abl and Lyn can be explained by increased hydrophobic interactions. It is reasonable that the hydrophobic effect of the 3-substituent, as expressed by $\pi$, significantly enhances the inhibitory activity.

Figure 5. NS-187 and imatinib bound to Abl and Lyn. (A) and (B) are X-ray structures of imatinib/Abl and NS-187/Abl complexes, respectively. (C) shows important interactions between NS-187 and Abl. Comparison of the CF$_3$ binding pocket in Abl and Lyn is shown in D–F. Meshes show the molecular surfaces of the kinases. The hydrophobic amino acids forming the hydrophobic pocket are shown in magenta. (D), (E) and (F) show the imatinib/Abl, NS-187/Abl, and NS-187/Lyn complexes, respectively. Adapted from Asaki et al. 2006 and Horio et al. 2007.
The inhibitory activities of the compounds are also linearly correlated with the Sterimol parameter B1, which expresses the minimum width of the 3-substituent ($r = 0.988$ for Abl and $r = 0.991$ for Lyn) (Horio et al. 2007); that is, the inhibitory effect increases with the size of the 3-substituent. Since the 3-substituent is located adjacent to the terminal dimethylaminopyrrolidine ring (E), it would be expected to hinder the rotation of the terminal ring. When we calculated the rotational barrier of the terminal ring by using the MMFF94x force field with MOE, we indeed found a restricted rotation about the bond connecting the D and E rings of NS-187 (Fig. 6). The CF$_3$ group not only reduces the flexibility of rotation of the terminal ring, but also helps NS-187 to adopt its bound (active) conformation (Kimura et al. 2006b). Because of the reduced loss of entropy upon binding, the inhibitory activity of the ligand would be expected to increase as the probability that it will adopt its active conformation increases. In addition, the reduced conformational flexibility could reduce the probability of binding to other proteins, thereby reducing the probability of adverse side effects.

Though kinase inhibitors bearing a CF$_3$ group are not rare, those with a CF$_3$ group adjacent to another group are rare. The adjacent location of these groups is a very characteristic structural feature of NS-187. The increased hydrophobicity and reduced conformational flexibility of NS-187 relative to imatinib cooperate to enhance its inhibitory activity against both Abl and Lyn kinase and reduce the probability of binding to off-target proteins.

**In Vitro Biological Activity of NS-187**

NS-187 blocks wild-type Bcr-Abl signaling

We compared the ability of NS-187 and imatinib to inhibit the phosphorylation of Bcr-Abl and other tyrosine kinases at the cellular level (Kimura et al. 2005). The IC$_{50}$ values of NS-187 against wild-type Bcr-Abl in human erythroleukemia K562 cells and human embryonic kidney 293T cells are 11 and 22 nM, respectively, while the corresponding values for imatinib are 280 and 1200 nM. NS-187 is therefore 25 to 55 times more potent than imatinib in blocking Bcr-Abl autophosphorylation. NS-187 suppresses the phosphorylation of platelet-derived growth factor receptor (PDGFR) and c-Kit with a potency similar to that of imatinib. However, while the potency ranking for imatinib is PDGFR > c-Kit > Bcr-Abl, the potency ranking for NS-187 is Bcr-Abl > PDGFR > c-Kit, so that the specificity of NS-187 for Bcr-Abl is greater than that of imatinib. Because inhibition of PDGFR or c-Kit could cause unpredictable adverse effects, specific inhibition of Bcr-Abl is desirable. Examination of the intracellular phosphorylation status of CrkL and ERK, downstream mediators of the effects of Bcr-Abl, revealed
that NS-187 inhibits the phosphorylation of these proteins in K562 cells at much lower concentrations than does imatinib. This inhibition of phosphorylation is also observed in the mouse ProB cell line BaF3 expressing wild-type Bcr-Abl (BaF3/wt). Taken together, these findings indicate that NS-187 is much more potent and specific than imatinib in blocking the effects of Bcr-Abl.

Antiproliferative activity of NS-187 against cells bearing wild-type or mutated Bcr-Abl

More than 40 point mutations within the Abl kinase domain have been reported (Hochhaus and Rosee, 2004). NS-187 at physiologically obtainable concentrations inhibits the phosphorylation of Bcr-Abl bearing the M244V, G250E, Q252H, Y253F, E255K, E255V, T315I, M351T, E355G, F317L, M351T, E355G, F359V, H396P, or F486S mutations, but it does not inhibit the phosphorylation of the T315I mutant (Kimura et al. 2005). Against all mutants except T315I, NS-187 is at least five times as potent as imatinib (Table 2).

NS-187 suppresses the growth of the Bcr-Abl+ cell lines K562, KU812 and BaF3/wt much more potently than does imatinib, but neither drug affects the proliferation of the Bcr-Abl-negative cell line U937 (Kimura et al. 2005). NS-187 exhibits a concentration-dependent antiproliferative effect against BaF3 cell lines expressing the Bcr-Abl mutants M244V, G250E, Q252H, Y253F, E255K, M351T or H396P, but has no effect on BaF3 cells expressing the T315I mutant. Bcr-Abl/wt, Q252H and M351T are especially sensitive to NS-187. Imatinib, meanwhile, is much less active against all cell lines tested (Naito et al. 2006). NS-187 therefore potently inhibits both the intracellular phosphorylation of most mutated Bcr-Abl kinases and the proliferation of cells expressing these kinases.

Mechanisms of NS-187-mediated cell death in Bcr-Abl+ leukemic cells

NS-187 augments the activity of pro-apoptotic Bcl-2 homology domain 3 (BH3)-only proteins and induces apoptosis in Bcr-Abl+ leukemic cells, as evidenced by DNA fragmentation, caspase-3 activation, and the loss of mitochondrial-outer-membrane permeabilization (Kuroda et al. 2007). ABT-737, an inhibitor of Bcl-2 and Bcl-XL, enhances the apoptosis induced by NS-187, even in cells with mutated Bcr-Abl that are less sensitive to NS-187, suggesting that Bcl-2-family-regulated, intrinsic apoptosis occurs through caspase activation. Even in the presence of the pan-caspase inhibitor zVAD-fmk, NS-187 still induces apoptosis in some cells, indicating the additional involvement of NS-187 in a caspase-independent apoptotic pathway. The observation of an increased number of cells showing the hallmarks of autophagy suggests that autophagy participates in the response against Bcr-Abl blockade. Inhibition of autophagy by chloroquine significantly enhances NS-187-induced cell death. These results may be useful in the design of a rational therapeutic approach for efficiently eradicating Bcr-Abl+ leukemic cells.

Inhibition of phosphorylated Abl by NS-187

Imatinib inhibits the kinase activity of the Tyr393-unphosphorylated form of the Abl kinase domain with an IC\textsubscript{50} value of 35 nM but has little effect on the phosphorylated form. In contrast, NS-187 effectively inhibits the kinase activity of both Tyr393-phosphorylated and Tyr393-unphosphorylated forms of Abl with respective IC\textsubscript{50} values of 72 nM and 30 nM, suggesting that NS-187 may have sufficiently high affinity for Bcr-Abl to enable it to bind even to an unfavourable conformation of the kinase (Naito et al. 2006).

---

**Table 2.** Effect of NS-187 and imatinib on in vitro phosphorylation of purified wild-type and point-mutated Abl kinase domains.

| Abl kinase | IC50 (nM) NS-187 | IC50 (nM) imatinib |
|------------|-----------------|-------------------|
| Wild type  | 72              | 1,100             |
| M244V     | 240             | 3,500             |
| G250E     | 160             | 2,000             |
| Q252H     | 410             | 2,100             |
| Y253F     | 81              | 1,500             |
| E255K     | 540             | 5,800             |
| E255V     | 1,400           | >10,000           |
| T315I     | >10,000         | >10,000           |
| F317L     | 760             | 1,900             |
| M351T     | 150             | 3,900             |
| E355G     | 580             | 7,100             |
| E359V     | 1,300           | >10,000           |
| H396P     | 95              | 1,400             |
| F486S     | 470             | 9,500             |

Adapted from Kimura et al. 2005.
Selectivity of NS-187 for Abl
A panel of 79 tyrosine kinases, including the five Src-family proteins Blk, Src, Fyn, Lyn and Yes, was assayed in the presence and absence of NS-187 or imatinib (Kimura et al. 2005). Concentrations of 0.1 µM NS-187 and 10 µM imatinib were used because these concentrations give equal inhibition of Abl. At 0.1 µM, NS-187 strongly inhibits only three of the 79 tyrosine kinases, that is, Abl, Arg and Lyn (Fyn is less strongly inhibited). At this concentration, NS-187 does not inhibit PDGFRα, PDGFRβ, Blk, Src or Yes. In contrast, 10 µM imatinib inhibits nine tyrosine kinases, that is, Abl, Arg, Blk, Flt3, Fyn, Lyn, PDGFRα, PDGFRβ and p70S6K. NS-187 therefore inhibits Abl more selectively than does imatinib. The IC50 values of NS-187 for Abl, Src and Lyn are 5.8, 1700 and 19 nM, respectively, while those of imatinib are 106, >10,000 and 352 nM, respectively. These findings suggest that NS-187 acts as an Abl/Lyn dual inhibitor while otherwise remaining highly specific.

In Vivo Anti-Tumor Activity of NS-187
Activity of NS-187 in mouse tumor models
The ability of NS-187 to suppress tumor growth was tested in two murine tumor models (Kimura et al. 2005). In one model, Balb/c-c-ntu/nu mice were injected subcutaneously with KU812 cells on Day 0 and given NS-187 or imatinib orally twice a day from Day 7 to Day 17. At 20 mg/kg/day, imatinib inhibits tumor growth slightly, while at 200 mg/kg/day, it inhibits tumor growth almost completely. NS-187, meanwhile, significantly inhibits tumor growth at only 0.2 mg/kg/day, while at 20 mg/kg/day it completely inhibits tumor growth without adverse effects. When mice were treated with NS-187 at 0.2 or 20 mg/kg/day, the estimated Cmax was 4 or 400 nM, respectively, comparable to the concentrations at which the in vitro effects of NS-187 are obtained. NS-187 is therefore at least 10-fold more potent than imatinib in vivo with complete inhibition of tumor growth as the end-point and at least 100-fold more potent with partial inhibition as the end-point. NS-187 was well tolerated by the mice.

In the other model, Balb/c-nu/nu mice intravenously injected with BaF3/wt cells were given NS-187 or imatinib orally for 11 days starting on Day 1. All seven untreated mice had died by Day 23 due to leukemic cell expansion, while all mice treated with 400 mg/kg/day imatinib had died by Day 25. NS-187, in contrast, significantly prolonged the survival of the mice in a dose-dependent manner compared with untreated mice.

To investigate the efficacy of NS-187 in a mouse model of leukemia, we tested its ability to block the growth of BaF3 cells expressing mutated Bcr-Abl in Balb/c-ntu/nu mice (Naito et al. 2006). Mice bearing BaF3 cells expressing M244V, Q252H, Y253F, E255K, T315I, M351T or H396P were treated with NS-187 or imatinib. Mice bearing BaF3 cells expressing wild-type Bcr-Abl or any mutant form of Bcr-Abl except T315I show significant prolongation of survival when they receive NS-187 at a dosage of 200 mg/kg/day, without any apparent signs of toxicity (Fig. 7). These in vivo results are consistent with the in vitro results. Imatinib, even at a dosage of 400 mg/kg/day, is much less effective. NS-187 results in the highest observed percentage increase in mean survival in mice bearing BaF3 cells expressing wild-type Bcr-Abl or Q252H or M351T, in good agreement with the in vitro results. Moreover, the rank-order of the IC50 values for cell growth inhibition is inversely correlated with the percentage increase in the mean survival of mice treated with NS-187. Thus, the efficacy of NS-187 in the mouse leukemia model mirrors its in vitro activity, a result which suggests that NS-187 will be clinically effective.

Activity of NS-187 against central nervous system leukemia
Because the penetration of imatinib into the central nervous system (CNS) is poor, the CNS can become a sanctuary site of relapse in patients on prolonged imatinib therapy. P-gp plays an important role in limiting the distribution of imatinib to the CNS, and it is well known that imatinib is a substrate for P-gp. Our preliminary pharmacokinetic study (Yokota et al. 2007) showed that the intracranial concentration of NS-187 is only 10% of its serum concentration, suggesting the involvement of P-gp. However, even though NS-187 is a substrate for P-gp, it still inhibits the proliferation of leukemic cells in the brain, whereas imatinib does not. NS-187 significantly prolongs the survival of mice in a dose-dependent manner in two CNS
leukemia murine models compared with imatinib. Furthermore, cyclosporine A, a P-gp inhibitor, augments the in vivo activity of NS-187 against CNS Ph+ leukemia, as shown by whole-brain fluorescence imaging (Fig. 8A–D) and survival curves (Fig. 8E and F). These findings indicate that NS-187 is a promising agent for the treatment of CNS Ph+ leukemia.

Phase I clinical study of NS-187 (INNO-406)
A phase I study of NS-187 (INNO-406) in 21 patients with Ph+ leukemia who were resistant to or intolerant of imatinib is in progress (Kantarjian et al. 2007).

Summary and Conclusions
Using X-ray crystallographic information and computer modeling, we have developed a highly potent and selective Abl/Lyn dual tyrosine kinase inhibitor, NS-187 (INNO-406). Its characteristic structural features are a trifluoromethyl group on the D ring that occupies a hydrophobic pocket of the Abl ligand-binding site and an adjacent dimethylaminopyrrolidine E ring whose rotation is restricted by the trifluoromethyl group. These features not only enhance inhibitory activity against Abl but also increase selectivity by reducing binding to off-target proteins. NS-187 has higher potency in inhibiting Abl than does imatinib and higher selectivity in inhibiting Lyn than do other SFK/Abl inhibitors. NS-187 is less sensitive to point mutations in the Abl kinase domain than are other
inhibitors such as imatinib, while maintaining a high selectivity for Abl and Lyn. NS-187 may be effective in the treatment of chronic myeloid leukemia with possible application to CNS leukemia and it may also be less liable to cause unfavorable side effects than are therapeutic agents that target multiple kinases, such as SFK inhibitors.

**Acknowledgements**

We thank Professor Taira Maekawa (Kyoto University) and Dr. Adam Craig (INNOVIVE Pharmaceuticals) for critically reviewing the manuscript and Dr. Gerald E. Smyth (Nippon Shinyaku) for his careful reading of the manuscript during its preparation.
References

Asaki, T., Sugiyama, Y., Hamamoto, T. et al. 2006. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg. Med. Chem. Lett., 16:1421–5.

Buchdunger, E., Zimmermann, J., Mert, H. et al. 1996. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56:100–4.

Cary, L.A., Klinghoffer, R.A., Sachsenmaier, C. and Cooper, J.A. 2002. SRC catalytic but not scaffolding function is needed for integrin-regulated tyrosine phosphorylation, cell migration, and cell spreading. Mol. Cell. Biol., 22:2427–40.

Cohen, P. 2002. Protein kinases—the major drug targets of the twenty-first century. Nat. Rev. Drug Discov., 1:309–15.

Cortes, J., Giles, F., O’Brien, S. et al. 2003. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood, 102:83–6.

Dai, Y., Rahmani, M., Corey, S.J. et al. 2004. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem., 279:34227–39.

Davis, M.E., Cai, H., McCann, L. et al. 2003. Role of c-Src in regulation of endothelial nitric oxide synthase expression during exercise training. Am. J. Physiol. Heart Circ. Physiol., 284:1449–53.

Deininger, M., Buchdunger, E. and Drucker, B.J. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105:2640–53.

Donato, N.J., Wu, Y.J., Stapley, J. et al. 2003. BCR-ABL independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101:690–8.

Druker, B.J., Sawyers, C.L., Kantarjian, H. et al. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344:1038–42.

Golias, J.M., Arndt, K., Etienne, C. et al. 2003. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res., 63:375–81.

Goldman, J.M. and Melo, J.V. 2003. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N. Engl. J. Med., 349:1451–64.

Gorre, M.E., Mohammed, M., Ellwood, K. et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293:876–80.

Hanks, S.K., Quinn, A.M. and Hunter, T. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science, 241:42–52.

Hanks, S.K. and Quinn, A.M. 1991. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol., 200:38–62.

Hegedus, T., Orfi, L., Seprodi, A. et al. 2002. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta., 1587:318–25.

Hochhaus, A. and Rosew, P. 2004. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia, 18:1321–31.

Hofmann, W.K., Jones, L.C., Lemp, N.A. et al. 2002. Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood, 99:1860–2.

Horio, T., Hamaekas, T., Inoue, T. et al. 2007. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg. Med. Chem. Lett., 17:12–7.

Kamitsuji, Y., Adachi, S., Kimura, S. et al. 2007. Cell death and autophagy induced by INNO-406, a novel Bcr-Abl inhibitor, in Philadelphia-positive leukemias. (Abstract no. 2768) 2007 Annual Meeting, American Association for Cancer Research.

Kantarjian, H., Talpaz, M., O’Brien, S. et al. 2004. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood, 103:2873–8.

Kantarjian, H.M., Cortes, J.E., Nagler, A. et al. 2007. A Phase 1 study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. (Abstract no. 2637) 2007 Annual Meeting, American Association for Cancer Research.

Kimura, S., Naito, H., Segawa, H. et al. 2005. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 106:3948–54.

Kimura, S. and Maekawa, T. 2006. Stem Cell Transplantation for Ph+ leukemias in the imatinib and post-imatinib eras. In: Davidson, D.F. ed. Bone Marrow Transplantation: New Research, New York: Nova Science Publishers, p 1–38.

Koizumi, S., Niwa, T., Hiraibayashi, K. et al. 2006b. Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor. Cancer Chemother. Pharmacol., 58(Suppl. 1):55–61.

Kuroda, J., Kimura, S., Strasser, A. et al. 2007. Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell, Death Diff., in press.

Manning, G., Whyte, D.B., Martinez, R. et al. 2002. The protein kinase complement of the human genome. Science, 298:1912–34.

Nagar, B., Bornmann, W.G., Pellicena, P. et al. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 62:4236–43.

Naito, H., Kimura, S., Nakaya, Y. et al. 2006. In vivo inhibitory effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on the proliferation of leukemic cells harbouring Abl kinase domain mutations. Leuk. Res., 30:1443–6.

Nardi, V., Azam, M. and Daley, G.Q. 2004. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol., 11:35–43.

Niwa, T. 2006. Elucidation of characteristic structural features of ligand binding sites of protein kinases: a neural network approach. J. Chem. Inf. Model., 46:2158–66.

O’Brien, S.G., Guilhott, F., Larson, R.A. et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 348:994–1004.

O’Brien, S., Giles, F., Talpaz, M. et al. 2003b. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer, 98:888–93.

O’Hare, T., Pollock, R., Stoffregen, E.P. et al. 2004. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood, 104:2532–9.

Ottmann, O.G., Druker, B.J., Sawyers, C.L. et al. 2002. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100:1965–71.

Ptasznik, A., Nakata, Y., Kalota, A. et al. 2004. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+)-leukemia cells. Nat. Med., 10:1187–9.

Tanaka, S., Amling, M., Neff, L. et al. 1996. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature, 383:528–31.

Toyoz, R.M., Wu, X.H., He, G. et al. 2001. Role of c-Src in the regulation of vascular contraction and Ca2+ signaling by angiotensin II in human vascular smooth muscle cells. J. Hypertens., 19:441–9.

Sawyers, C.L. 1999. Chronic myeloid leukemia. N. Engl. J. Med., 340:330–40.

Shah, N.P., Tran, C., Lee, F.Y. et al. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305:399–401.
Weisberg, E., Manley, P.W., Breitenstein, W. et al. 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7:129–41.

Wisniewski, D., Lambek, C.L., Liu, C. et al. 2002. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res., 62:4244–55.

Yokota, A., Kimura, S., Oyama, T. et al. 2007. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 109:306–14.

Zimmermann, J., Buchdunger, E., Mett, H. et al. 1997. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett., 7:187–92.